FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000201211> ?p ?o ?g. }

• W3000201211 endingPage "816" @default.
• W3000201211 startingPage "807" @default.
• W3000201211 abstract "Abstract Aim Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD) linked to atherogenic dyslipidaemia and postprandial hyperlipidaemia. Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, improves CVD risk by reducing the concentration of low‐density lipoprotein‐cholesterol (LDL‐C). However, effects of PCK9 inhibitors on other aspects of diabetic dyslipidaemia, particularly in the postprandial situation, are less clear. Material and Methods Twelve male patients with T2DM on an intensive insulin regimen completed a 6‐week randomized, double‐blind, placebo‐controlled, proof‐of‐concept study. Participants received three biweekly dosages of subcutaneous alirocumab (150 mg) or placebo. Before and after the intervention, fasting and postprandial triglyceride (TG) plasma levels, apolipoprotein (apo) B48, lipoprotein composition isolated by ultracentrifugation, vascular function and markers of inflammation were evaluated. Results Alirocumab treatment reduced fasting plasma TG levels (between group median change −24.7%; P = 0.018) and fasting apoB48 serum levels (−35.9%; P = 0.039) compared with placebo. Alirocumab reduced the plasma TG area under the curve (AUC) (−26.4%; P = 0.006) and apoB48 AUC (−55.7%; P = 0.046), as well as plasma TG incremental AUC (−21.4%; P = 0.04) and apoB48 incremental AUC (−26.8%; P = 0.02). In addition, alirocumab reduced fasting and postprandial TG levels in very low‐density lipoprotein (VLDL) and LDL. Alirocumab improved fasting pulse wave velocity, but no changes in postprandial markers of inflammation were observed. Conclusions In addition to the well‐known LDL‐C‐reducing effects, 6 weeks of alirocumab treatment lowered both fasting and postprandial plasma TG levels by reducing the TG levels in VLDL and LDL and the concentration of intestinal remnants." @default.
• W3000201211 created "2020-01-23" @default.
• W3000201211 creator A5008119579 @default.
• W3000201211 creator A5012982700 @default.
• W3000201211 creator A5018924568 @default.
• W3000201211 creator A5022429591 @default.
• W3000201211 creator A5023302477 @default.
• W3000201211 creator A5023843843 @default.
• W3000201211 creator A5035385427 @default.
• W3000201211 creator A5045683286 @default.
• W3000201211 creator A5058942319 @default.
• W3000201211 creator A5062150957 @default.
• W3000201211 creator A5067082531 @default.
• W3000201211 creator A5074027914 @default.
• W3000201211 date "2020-01-27" @default.
• W3000201211 modified "2023-10-11" @default.
• W3000201211 title "A placebo‐controlled proof‐of‐concept study of alirocumab on postprandial lipids and vascular elasticity in insulin‐treated patients with type 2 diabetes mellitus" @default.
• W3000201211 cites W132443541 @default.
• W3000201211 cites W1968171440 @default.
• W3000201211 cites W1977335231 @default.
• W3000201211 cites W1990545107 @default.
• W3000201211 cites W1991377524 @default.
• W3000201211 cites W2012799511 @default.
• W3000201211 cites W2020659754 @default.
• W3000201211 cites W2022751485 @default.
• W3000201211 cites W2027904194 @default.
• W3000201211 cites W2038970022 @default.
• W3000201211 cites W2043869729 @default.
• W3000201211 cites W2057651652 @default.
• W3000201211 cites W2061161673 @default.
• W3000201211 cites W2063862132 @default.
• W3000201211 cites W2069993714 @default.
• W3000201211 cites W2073294069 @default.
• W3000201211 cites W2077244492 @default.
• W3000201211 cites W2077440910 @default.
• W3000201211 cites W2077829695 @default.
• W3000201211 cites W2086102619 @default.
• W3000201211 cites W2097870088 @default.
• W3000201211 cites W2099486981 @default.
• W3000201211 cites W2104005551 @default.
• W3000201211 cites W2108018713 @default.
• W3000201211 cites W2108493094 @default.
• W3000201211 cites W2109896814 @default.
• W3000201211 cites W2117470164 @default.
• W3000201211 cites W2127329804 @default.
• W3000201211 cites W2131142277 @default.
• W3000201211 cites W2137211946 @default.
• W3000201211 cites W2140424137 @default.
• W3000201211 cites W2142407152 @default.
• W3000201211 cites W2149433053 @default.
• W3000201211 cites W2150436995 @default.
• W3000201211 cites W2156274620 @default.
• W3000201211 cites W2165416930 @default.
• W3000201211 cites W2167788046 @default.
• W3000201211 cites W2169582126 @default.
• W3000201211 cites W2396920814 @default.
• W3000201211 cites W2563852152 @default.
• W3000201211 cites W2582040770 @default.
• W3000201211 cites W2606281213 @default.
• W3000201211 cites W2731199601 @default.
• W3000201211 cites W2754562397 @default.
• W3000201211 cites W2807324205 @default.
• W3000201211 cites W2891231432 @default.
• W3000201211 cites W2899997727 @default.
• W3000201211 doi "https://doi.org/10.1111/dom.13960" @default.
• W3000201211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31912632" @default.
• W3000201211 hasPublicationYear "2020" @default.
• W3000201211 type Work @default.
• W3000201211 sameAs 3000201211 @default.
• W3000201211 citedByCount "11" @default.
• W3000201211 countsByYear W30002012112020 @default.
• W3000201211 countsByYear W30002012112021 @default.
• W3000201211 countsByYear W30002012112022 @default.
• W3000201211 countsByYear W30002012112023 @default.
• W3000201211 crossrefType "journal-article" @default.
• W3000201211 hasAuthorship W3000201211A5008119579 @default.
• W3000201211 hasAuthorship W3000201211A5012982700 @default.
• W3000201211 hasAuthorship W3000201211A5018924568 @default.
• W3000201211 hasAuthorship W3000201211A5022429591 @default.
• W3000201211 hasAuthorship W3000201211A5023302477 @default.
• W3000201211 hasAuthorship W3000201211A5023843843 @default.
• W3000201211 hasAuthorship W3000201211A5035385427 @default.
• W3000201211 hasAuthorship W3000201211A5045683286 @default.
• W3000201211 hasAuthorship W3000201211A5058942319 @default.
• W3000201211 hasAuthorship W3000201211A5062150957 @default.
• W3000201211 hasAuthorship W3000201211A5067082531 @default.
• W3000201211 hasAuthorship W3000201211A5074027914 @default.
• W3000201211 hasBestOaLocation W30002012112 @default.
• W3000201211 hasConcept C126322002 @default.
• W3000201211 hasConcept C134018914 @default.
• W3000201211 hasConcept C142724271 @default.
• W3000201211 hasConcept C204787440 @default.
• W3000201211 hasConcept C27081682 @default.
• W3000201211 hasConcept C2777180221 @default.
• W3000201211 hasConcept C2778163477 @default.
• W3000201211 hasConcept C2778199505 @default.
• W3000201211 hasConcept C2779306644 @default.
• W3000201211 hasConcept C2780072125 @default.

• next